Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study

Andreas Klaus Pfeifer; Ulrich Knigge; Jann Mortensen; Peter Oturai; Anne Kiil Berthelsen; Annika Loft; Tina Binderup; Palle Rasmussen; Dennis Ringkjøbing Elema; Thomas Levin Klausen; Søren Holm; Eric von Benzon; Liselotte Højgaard; Andreas Kjaer

doi:10.2967/jnumed.111.101469

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study

Andreas Klaus Pfeifer, Ulrich Knigge, Jann Mortensen, Peter Oturai, Anne Kiil Berthelsen, Annika Loft, Tina Binderup, Palle Rasmussen, Dennis Ringkjøbing Elema, Thomas Levin Klausen, Søren Holm, Eric von Benzon, Liselotte Højgaard, Andreas Kjaer

Research output: Contribution to journal › Journal article › Research › peer-review

146 Citations (Scopus)

Abstract

The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).

Original language	English
Journal	Journal of Nuclear Medicine
Volume	53
Issue number	8
Pages (from-to)	1207-15
Number of pages	9
ISSN	0161-5505
DOIs	https://doi.org/10.2967/jnumed.111.101469
Publication status	Published - Aug 2012

Keywords

Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Neuroendocrine Tumors
Octreotide
Organometallic Compounds
Positron-Emission Tomography
Quality Control
Radiation Dosage
Radiochemistry
Tomography, Emission-Computed, Single-Photon

Access to Document

10.2967/jnumed.111.101469

Cite this

Pfeifer, A. K., Knigge, U., Mortensen, J., Oturai, P., Berthelsen, A. K., Loft, A., Binderup, T., Rasmussen, P., Elema, D. R., Klausen, T. L., Holm, S., von Benzon, E., Højgaard, L., & Kjaer, A. (2012). Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. Journal of Nuclear Medicine, 53(8), 1207-15. https://doi.org/10.2967/jnumed.111.101469

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE : first-in-humans study. / Pfeifer, Andreas Klaus; Knigge, Ulrich ; Mortensen, Jann; Oturai, Peter; Berthelsen, Anne Kiil; Loft, Annika; Binderup, Tina; Rasmussen, Palle; Elema, Dennis Ringkjøbing; Klausen, Thomas Levin; Holm, Søren; von Benzon, Eric; Højgaard, Liselotte ; Kjaer, Andreas.

In: Journal of Nuclear Medicine, Vol. 53, No. 8, 08.2012, p. 1207-15.

Research output: Contribution to journal › Journal article › Research › peer-review

Pfeifer, Andreas Klaus ; Knigge, Ulrich ; Mortensen, Jann ; Oturai, Peter ; Berthelsen, Anne Kiil ; Loft, Annika ; Binderup, Tina ; Rasmussen, Palle ; Elema, Dennis Ringkjøbing ; Klausen, Thomas Levin ; Holm, Søren ; von Benzon, Eric ; Højgaard, Liselotte ; Kjaer, Andreas. / Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE : first-in-humans study. In: Journal of Nuclear Medicine. 2012 ; Vol. 53, No. 8. pp. 1207-15.

@article{57e1afc414884017b3eee9ba9de588fd,

title = "Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study",

abstract = "The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).",

keywords = "Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Positron-Emission Tomography, Quality Control, Radiation Dosage, Radiochemistry, Tomography, Emission-Computed, Single-Photon",

author = "Pfeifer, {Andreas Klaus} and Ulrich Knigge and Jann Mortensen and Peter Oturai and Berthelsen, {Anne Kiil} and Annika Loft and Tina Binderup and Palle Rasmussen and Elema, {Dennis Ringkj{\o}bing} and Klausen, {Thomas Levin} and S{\o}ren Holm and {von Benzon}, Eric and Liselotte H{\o}jgaard and Andreas Kjaer",

year = "2012",

month = aug,

doi = "10.2967/jnumed.111.101469",

language = "English",

volume = "53",

pages = "1207--15",

journal = "The Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine",

number = "8",

}

TY - JOUR

T1 - Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE

T2 - first-in-humans study

AU - Pfeifer, Andreas Klaus

AU - Knigge, Ulrich

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Berthelsen, Anne Kiil

AU - Loft, Annika

AU - Binderup, Tina

AU - Rasmussen, Palle

AU - Elema, Dennis Ringkjøbing

AU - Klausen, Thomas Levin

AU - Holm, Søren

AU - von Benzon, Eric

AU - Højgaard, Liselotte

AU - Kjaer, Andreas

PY - 2012/8

Y1 - 2012/8

N2 - The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).

AB - The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neuroendocrine Tumors

KW - Octreotide

KW - Organometallic Compounds

KW - Positron-Emission Tomography

KW - Quality Control

KW - Radiation Dosage

KW - Radiochemistry

KW - Tomography, Emission-Computed, Single-Photon

U2 - 10.2967/jnumed.111.101469

DO - 10.2967/jnumed.111.101469

M3 - Journal article

C2 - 22782315

VL - 53

SP - 1207

EP - 1215

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -